4519 Stock Overview
Engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Chugai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥6,383.00 |
| 52 Week High | JP¥7,869.00 |
| 52 Week Low | JP¥4,572.00 |
| Beta | 0.50 |
| 11 Month Change | -7.29% |
| 3 Month Change | -11.59% |
| 1 Year Change | 29.21% |
| 33 Year Change | 57.29% |
| 5 Year Change | 99.22% |
| Change since IPO | 1,419.76% |
Recent News & Updates
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Oct 30
Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 12%: Here's What Analysts Think Will Happen Next
Oct 29Recent updates
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Oct 30Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 12%: Here's What Analysts Think Will Happen Next
Oct 29Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Oct 15Should You Be Adding Chugai Pharmaceutical (TSE:4519) To Your Watchlist Today?
Oct 12Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Sep 24Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Jul 30Chugai Pharmaceutical (TSE:4519) Is Due To Pay A Dividend Of ¥41.00
Jul 27Estimating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)
Jul 15Chugai Pharmaceutical (TSE:4519) Is Increasing Its Dividend To ¥41.00
Jun 19Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't
Jun 17Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year
May 04We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings
May 01Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Apr 26Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected
Mar 01Shareholder Returns
| 4519 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -10.5% | -4.5% | -0.4% |
| 1Y | 29.2% | 8.6% | 11.4% |
Return vs Industry: 4519 exceeded the JP Pharmaceuticals industry which returned 8.6% over the past year.
Return vs Market: 4519 exceeded the JP Market which returned 11.4% over the past year.
Price Volatility
| 4519 volatility | |
|---|---|
| 4519 Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.6% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4519's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4519's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 7,604 | Osamu Okuda | www.chugai-pharm.co.jp |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Chugai Pharmaceutical Co., Ltd. Fundamentals Summary
| 4519 fundamental statistics | |
|---|---|
| Market cap | JP¥10.50t |
| Earnings (TTM) | JP¥386.96b |
| Revenue (TTM) | JP¥1.14t |
27.1x
P/E Ratio9.2x
P/S RatioIs 4519 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4519 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.14t |
| Cost of Revenue | JP¥337.17b |
| Gross Profit | JP¥805.18b |
| Other Expenses | JP¥418.22b |
| Earnings | JP¥386.96b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | 235.16 |
| Gross Margin | 70.48% |
| Net Profit Margin | 33.87% |
| Debt/Equity Ratio | 0% |
How did 4519 perform over the long term?
See historical performance and comparison